Abstract:Background: Immunotherapy is a promising approach for lung cancer, but its effectiveness is limited by tumor heterogeneity. Nanoparticle-based targeted drug delivery systems offer advantages such as targeted drug-loading capacity, and hypotoxicity, showing great potential in improving therapeutic efficacy. This study introduces a targeted drug delivery strategy based on immune-activating nanoparticles that achieves precise drugs delivery in tumor areas. Consequently, this approach remodels the microenvironment and induces tumor cytotoxicity. Method: In this study, we first constructed a targeted nanoparticle delivery system FP@CC. The vehicle utilized lung adenocarcinoma cell membranes as the outer shell and encapsulated iron-platinum nanoparticles and STING agonist Vadimezan. Then, TREM2 antibodies were conjugated on the outer layer. The structure of FP@CC-aT2 was characterized by HADDF-STEM and its safety was evaluated by hemolysis test. In vitro, its ability to induce death was verified by AM/PI staining, and to induce ferroptosis was detected by C11 assay. Furthermore, we evaluated its antitumor effects in subcutaneous tumor models. The composition of immune cells within the tumor microenvironment was analyzed using flow cytometry. Results: We initially performed HADDF-STEM analysis on the nanoparticle precursor FP/Vad@CC, revealing its uniform sphericity. For security, no significant hemolysis was observed at different concentrations of FP/Vad@CC. Then, the structures of FP/Vad@CC-aT2 and FP/Vad@CC are relatively stable (Fig 1).The number of dead cells significantly increased after deal with FP@CC, and the effect was significantly enhanced when combined with X-ray. Moreover, C11, utilizing to assess the changes in intracellular reactive oxygen species (ROS), found that FP@CC led to a significant increase in ROS, comparable to induction by H2O2. Both could be effectively prevented by ferroptosis inhibitor(Fig 2).In vivo, FP/Vad@CC-aT2 was applied to a subcutaneous tumor model in C57. It exhibited excellent therapeutic efficacy and biocompatibility. Flow cytometry revealed that FP/Vad@CC-aT2 had the anticipated impact on macrophages within the tumor: a significant reduction in CD11high/CD206high cells and opposite in the ratio of M1/M2-like macrophages (Fig 3). Conclusion: This study developed a targeted drug delivery strategy, FP/Vad@CC-aT2, to improve the tumor microenvironment (TME). We conducted preliminary experiments in vitro and in vivo to validate its physicochemical properties and tumor inhibitory effects, including the induction of ferroptosis. We assessed its safety in mouse and obtained initial evidence of FP/Vad@CC-aT2's ability to remodel the subtypes of macrophage.Moving forward, we will validate its therapeutic and impact on the TME after surgical procedures. Citation Format: Haiyu Zhou, Hongrui Qiu, Shiying Li, Bin Xu, Shengbo Liu, Huili Wang, Hengliang Hou. Engineering cell membrane nanoparticlesenhance immunotherapy and radiodynamic therapy for lung adenocarcinoma by promoting cGAS-STING and ferroptosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5762.

Bystander Effects in FUS1-nanoparticle-mediated Human Lung Cancer Gene Therapy

Cell To Cell Contact Required For Bystander Effect Of The Tnf-Related Apoptosis-Inducing Ligand (Trail) Gene

Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma

Synergistic Tumor Suppression by Coexpression of FUS1 and P53 is Associated with Down-Regulation of Murine Double Minute-2 and Activation of the Apoptotic Protease-Activating Factor 1-Dependent Apoptotic Pathway in Human Non-Small Cell Lung Cancer Cells.

Bystander Signaling Between Glioma Cells And Fibroblasts Targeted With Counted Particles

Focused Ultrasound-Mediated Small-Molecule Delivery to Potentiate Immune Checkpoint Blockade in Solid Tumors

Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells

Overcoming Gefitinib Resistance in Nsclc Via Inactivation of the Pi3k/Akt Signaling Pathway by A Combination of Fus1 Nanoparticles and Egfr Inhibitors.

Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo

Abstract 5762: Engineering cell membrane nanoparticlesenhance immunotherapy and radiodynamic therapy for lung adenocarcinoma by promoting cGAS-STING and ferroptosis

A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer

Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer.

Powerful Anticolon Tumor Effect of Targeted Gene Immunotherapy Using Folate-Modified Nanoparticle Delivery of CCL19 To Activate the Immune System

Suppression of Human MDA-MB-435S Tumor by U6 Promoter-Driven Short Hairpin RNAs Targeting Focal Adhesion Kinase

Antitumor bystander effect induced by radiation-inducible target gene therapy combined with α particle irradiation

The FUS1 Gene Inhibits EC109 Cell Growth Mediated by a Lentivirus Vector

[Anti-Tumor and Bystander Effects of Cationic Liposome-Mediated CD/5-FC Suicide Gene System Combined with Interferon-Gamma in Vivo].

Multifunctional Nucleus-Targeting Nanoparticles with Ultra-High Gene Transfection Efficiency for in Vivo Gene Therapy

[Bystander Effect of Target-Regulated Uracil Phosphoribosyltransferase/5-Fluorouracil Suicide Gene System on Prostate Cancer Cell].

Hypoxia and Proton microbeam: Role of Gap Junction Intercellular Communication in Inducing Bystander Responses on Human Lung Cancer Cells and Normal Cells

Anti-tumor Effects of P53n15-Based Fusion Peptide in the Transfected H1299 Lung Cancer Cells